文献速递淋巴瘤

新型devimistat在经重度治疗的伯基特淋巴瘤中实现完全缓解:一项2期试验

Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.
PubMed 文献 · Blood Adv · 2025-01-01

这项2期试验评估devimistat治疗复发/难治性MYC驱动侵袭性B细胞淋巴瘤的疗效,给药方案为每14天连续5天、共2周期,随后每21天连续5天维持治疗直至进展、毒性或移植。13例复发/难治性伯基特淋巴瘤中2例达完全缓解,完全缓解率为15%;2例复发/难治性浆母细胞淋巴瘤和9例复发/难治性双打击/三打击淋巴瘤均无缓解。

要点

  • 复发/难治性伯基特淋巴瘤13例中2例达完全缓解,完全缓解率15%。
  • 2例复发/难治性浆母细胞淋巴瘤和9例复发/难治性双打击/三打击淋巴瘤均无缓解。
  • 3例出现至少可能与研究药物相关的3级事件:中性粒细胞减少、血小板减少、头痛、非心源性胸痛和肌钙蛋白升高。

核心结论

  • 鉴于复发/难治性MYC驱动侵袭性B细胞淋巴瘤在当前标准治疗下预后极差且devimistat的完全缓解率低,应努力改善这些恶性肿瘤的一线治疗结局,并在复发/难治背景下探索新疗法。

研究设计与样本

  • 2期试验,纳入复发/难治性伯基特淋巴瘤、复发/难治性浆母细胞淋巴瘤和复发/难治性双打击淋巴瘤患者。
  • devimistat每日给药连续5天、每14天为一周期、共2周期,随后每21天连续5天维持治疗直至进展、毒性或移植。
  • 试验注册号为NCT03793140。

主要发现

  • 2例复发/难治性浆母细胞淋巴瘤和9例复发/难治性双打击/三打击淋巴瘤均未见缓解。
  • 13例复发/难治性伯基特淋巴瘤中2例达完全缓解,完全缓解率为15%,其余患者出现快速疾病进展。
  • 复发/难治性伯基特淋巴瘤患者的中位随访时间为1个月(范围0-47)。
  • 2例复发/难治性伯基特淋巴瘤完全缓解患者中,1例缓解持续8个月,另1例至数据截止时缓解持续,为入组后17个月。
  • 共3例出现至少可能与研究药物相关的3级事件:中性粒细胞减少、血小板减少、头痛、非心源性胸痛和肌钙蛋白升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 复发/难治性伯基特淋巴瘤患者的中位随访时间为1个月(范围0-47)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with primary refractory or relapsed (R/R) MYC-driven aggressive B-cell lymphomas, such as Burkitt lymphoma (BL), plasmablastic lymphoma (PBL), and double-hit lymphoma (DHL)/triple-hit lymphoma (THL), have a dismal prognosis with few survivors. The deregulated MYC protein drives proliferation with dependence on tricarboxylic acid cycle intermediates as biosynthetic precursors. Devimistat disrupts mitochondrial production of adenosine triphosphate and biosynthetic intermediates. We conducted a phase 2 trial to explore the efficacy of devimistat in R/R-BL, R/R-PBL, and R/R-DHL, administered daily for 5 days every 14 days for 2 cycles, followed by maintenance for 5 days every 21 days until progression, toxicity, or transplant. No responses were seen in the 2 enrolled patients with R/R-PBL and 9 with R/R-DHL/THL. Among the 13 patients with R/R-BL, 2 had a complete response (CR), resulting in a CR rate (CRR) of 15%, whereas the others experienced rapid disease progression. The median follow-up time for patients with R/R-BL was 1 month (range, 0-47). Among the 2 patients with R/R-BL CR, the response duration was 8 months in 1 and ongoing at the time of data cutoff, 17 months after study entry. Overall, 3 patients had grade 3 events at least possibly related to the study drug: neutropenia, thrombocytopenia, headache, noncardiac chest pain, and increase of troponin. Considering the dismal prognosis of R/R MYC-driven aggressive B-cell lymphomas with the current standard of care and low CRR with devimistat, efforts should be made to improve the outcome of these malignancies with their first line of therapy and explore novel therapies in the R/R setting. This trial was registered at www.ClinicalTrials.gov as #NCT03793140.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Steiner R, Nikolaenko L, Nair R, et al. Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial. Blood Adv. 2025. PMID: 40674734. doi:10.1182/bloodadvances.2025016168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。